These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1479 related items for PubMed ID: 29395273

  • 1. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, GWPCARE4 Study Group.
    Lancet; 2018 Mar 17; 391(10125):1085-1096. PubMed ID: 29395273
    [Abstract] [Full Text] [Related]

  • 2. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS.
    Epilepsy Curr; 2019 Mar 17; 19(2):93-95. PubMed ID: 30955420
    [Abstract] [Full Text] [Related]

  • 3. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group.
    N Engl J Med; 2018 May 17; 378(20):1888-1897. PubMed ID: 29768152
    [Abstract] [Full Text] [Related]

  • 4. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR.
    Lancet Neurol; 2016 Mar 17; 15(3):270-8. PubMed ID: 26724101
    [Abstract] [Full Text] [Related]

  • 5. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA.
    Pediatrics; 2006 Aug 17; 118(2):e371-8. PubMed ID: 16847080
    [Abstract] [Full Text] [Related]

  • 6. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
    Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C.
    Epilepsia; 2019 Mar 17; 60(3):419-428. PubMed ID: 30740695
    [Abstract] [Full Text] [Related]

  • 7. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
    Privitera M, Bhathal H, Wong M, Cross JH, Wirrell E, Marsh ED, Mazurkiewicz-Beldzinska M, Villanueva V, Checketts D, Knappertz V, VanLandingham K.
    Epilepsia; 2021 May 17; 62(5):1130-1140. PubMed ID: 33797076
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, Miller I, Nichol K, Park Y, Segal E, Seltzer L, Szaflarski JP, Thiele EA, Weinstock A, CBD EAP study group.
    Epilepsy Res; 2019 Aug 17; 154():13-20. PubMed ID: 31022635
    [Abstract] [Full Text] [Related]

  • 9. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.
    Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K.
    Epilepsy Res; 2014 Nov 17; 108(9):1627-36. PubMed ID: 25219353
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
    Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, Olson HE, Specchio N, Fleming TR, Aimetti AA, Gasior M, Devinsky O, Marigold Trial Group.
    Lancet Neurol; 2022 May 17; 21(5):417-427. PubMed ID: 35429480
    [Abstract] [Full Text] [Related]

  • 11. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
    Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V, GWPCARE6 Study Group.
    JAMA Neurol; 2021 Mar 01; 78(3):285-292. PubMed ID: 33346789
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
    Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M.
    CNS Drugs; 2018 Oct 01; 32(10):905-916. PubMed ID: 30132269
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
    Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, Guerrini R, Zuberi SM, Nabbout R, Riney K, Shore S, Agarwal A, Lock M, Farfel GM, Galer BS, Gammaitoni AR, Davis R, Gil-Nagel A.
    JAMA Neurol; 2022 Jun 01; 79(6):554-564. PubMed ID: 35499850
    [Abstract] [Full Text] [Related]

  • 14. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
    Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, Saneto RP, Checketts D, Dunayevich E, Knappertz V, GWPCARE2 Study Group.
    JAMA Neurol; 2020 May 01; 77(5):613-621. PubMed ID: 32119035
    [Abstract] [Full Text] [Related]

  • 15. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.
    Wheless JW, Isojarvi J, Lee D, Drummond R, Benbadis SR.
    Epilepsy Behav; 2014 Dec 01; 41():47-52. PubMed ID: 25282105
    [Abstract] [Full Text] [Related]

  • 16. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
    Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group.
    N Engl J Med; 2017 May 25; 376(21):2011-2020. PubMed ID: 28538134
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
    French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN.
    Lancet; 2016 Oct 29; 388(10056):2153-2163. PubMed ID: 27613521
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
    Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M.
    Drugs; 2018 Nov 29; 78(17):1791-1804. PubMed ID: 30390221
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.
    Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K.
    Epilepsy Res; 2016 Mar 29; 121():1-7. PubMed ID: 26827266
    [Abstract] [Full Text] [Related]

  • 20. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.
    Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P.
    N Engl J Med; 1997 Dec 18; 337(25):1807-12. PubMed ID: 9400037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.